In a murine model of BRAF V600E/PTEN null melanoma transgenic mice, an oral TGF-β inhibitor combined with intraperitoneal anti-CTLA-4 antibody led to an increased CD8+ effector T cell: Treg cell ratio and suppression of primary and metastatic melanoma tumor growth [115]. Here, CTLA4 is linked to melanoma.